Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

by Bardia, A., Carmagnani Pestana, R., Cortes, J., Corti, C., Curigliano, G., Modi, S., Soria, J.-C, Tarantino, P., Tolaney, S.M
Published 2022

Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives

by Amin, S., Beusterien, K., Janelle Cambron-Mellott, M., MacUlaitis, M.C, McLaurin, K., Mulvihill, E., Shinde, R., Tolaney, S.M
Published 2022

Immunotherapy for early triple negative breast cancer: research agenda for the next decade

by Andrè, F., Bianchini, G., Cortes, J., Corti, C., Curigliano, G., Mittendorf, E.A, Rugo, H., Schmid, P., Tarantino, P., Tolaney, S.M
Published 2022

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

by Abramson, V., Arkenau, H.T, Dean, E., Diaz-Padilla, I., Dong, J., Ferrer-Playan, J., Fleuranceau-Morel, P., Goddemeier, T., Grombacher, T., Haddad, T.C, Lord, S.R, Middleton, M., Plummer, R., Shapiro, G.I, Telli, M.L, Tolaney, S.M, Tutt, A., Wesolowski, R.
Published 2022

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a ra...

by Abramson, V., Albain, K., Ardman, B., Barroso-Sousa, R., Barry, W., Bose, R., Briccetti, F., Burstein, H., Cheng, K., Constantine, M., Dang, C., DeFusco, P., DeMeo, M., Faggen, M., Forero-Torres, A., Gadi, V.K, Garrett, A.M, Gelber, R.D, Hart, L., Hu, J., Isakoff, S.J, Jankowitz, R.C, Krop, I., Liu, M., Marcom, K., Mulvey, T., Nanda, R., Partridge, A., Pohlmann, P.R, Ramaswamy, B., Reeder-Hayes, K., Rimawi, M., Rosenberg, S.M, Ruddy, K.J, Rugo, H.S, Schneider, B., Tarantino, P., Tayob, N., Tolaney, S.M, Trippa, L., Tung, N., Valero, V., Van Poznak, C., Weckstein, D., Winer, E.P, Wolff, A.C, Yardley, D.A, Zheng, Y., Zuckerman, D.
Published 2022